The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1188-1194.e3, December 2009

Adrenergic β2-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol

  • Kaninika Basu, MBBS

      Affiliations

    • Royal Alexandra Children's Hospital, Brighton and Sussex Medical School, Brighton, United Kingdom
    • Tayside Institute of Child Health, Ninewells Hospital and Medical School, Dundee, United Kingdom
    • These authors contributed equally to this work.
  • ,
  • Colin N.A. Palmer, PhD

      Affiliations

    • Population Pharmacogenetics Group, Biomedical Research Institute, Ninewells Hospital and Medical School, Dundee, United Kingdom
    • These authors contributed equally to this work.
  • ,
  • Roger Tavendale, PhD

      Affiliations

    • Population Pharmacogenetics Group, Biomedical Research Institute, Ninewells Hospital and Medical School, Dundee, United Kingdom
  • ,
  • Brian J. Lipworth, FRCP, MD

      Affiliations

    • Asthma and Allergy Research Group, Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee, United Kingdom
  • ,
  • Somnath Mukhopadhyay, FRCPCH, PhD

      Affiliations

    • Royal Alexandra Children's Hospital, Brighton and Sussex Medical School, Brighton, United Kingdom
    • Tayside Institute of Child Health, Ninewells Hospital and Medical School, Dundee, United Kingdom
    • Corresponding Author InformationReprint requests: Somnath Mukhopadhyay, FRCPCH, PhD, Royal Alexandra Children's Hospital, Brighton BN2 5BE, United Kingdom.

Received 24 December 2008; received in revised form 30 June 2009; accepted 24 July 2009. published online 05 October 2009.

Background

On-demand inhaled albuterol is commonly prescribed worldwide. We have shown that the Arg16 allele of the adrenergic β2-receptor agonist gene (ADRB2) predisposes to exacerbations in young asthmatic patients taking regular salmeterol.

Objective

We have now extended our previous population by 636 patients and explored the role of the Arg16 allele on asthma exacerbations in the context of the use of on-demand albuterol and regular salmeterol.

Methods

Arg/Gly status at position 16 of ADRB2 was assessed in 1182 young asthmatic patients (age, 3-22 years) from Scotland. Asthma exacerbations, use of β-agonists and other medications over the previous 6 months, and lung function were also studied.

Results

An increased risk of exacerbations per copy of he Arg16 allele was observed in asthmatic patients, regardless of treatment regimen (odds ratio [OR], 1.30; 95% CI, 1.09-1.55; P = .003). This appears to be largely due to exposure to β2-agonists because the risk of exacerbations observed in patients with the Arg16 allele was only observed in those receiving daily inhaled long- or short-acting β2-agonist treatment (OR, 1.64; 95% CI, 1.22-2.20; P = .001). In contrast, there was no genotypic risk for exacerbations in patients using inhaled β2-agonists less than once a day (OR, 1.08; 95% CI, 0.85-1.36; P = .525). The Arg16 genotype–associated risk for exacerbations was significantly different in those exposed to β2-agonists daily versus those that were not (test for interaction, P = .022).

Conclusion

The Arg16 genotype of ADRB2 is associated with exacerbations in asthmatic children and young adults exposed daily to β2-agonists, regardless of whether the exposure is to albuterol or long-acting agonists, such as salmeterol.

Key words: Asthma, child, polymorphism, asthma exacerbations, albuterol, salmeterol, β2-adrenoceptor, adrenergic β2-receptor agonist gene

Abbreviations used: ADRB2, Adrenergic β2-receptor agonist gene, BTS, British Thoracic Society, OR, Odds ratio

 

 Support for the study was approved by the Gannochy Trust (Perth, Scotland), Scottish Enterprises Tayside, and the Perth and Kinross Council. C. N. A. P. is supported by the Scottish Executive Genetic Health Initiative Award.

 Disclosure of potential conflict of interest: B. J. Lipworth has provided consulting advice regarding the fluticasone/formoterol combination for Mundipharma, provided a speakers' bureau talk on budesonide formoterol for AstraZeneca and a speakers' bureau talk on heterogeneity in asthma and airway remodeling for Merck, has received research support from Merck Sharpe & Dohme and Neolab, and has provided legal consultation on formoterol equivalence for TEVA. S. Mukhopadhyay has served as an expert advisor for and received research support from Merck Sharpe & Dohme. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(09)01150-6

doi:10.1016/j.jaci.2009.07.043

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1188-1194.e3, December 2009